Oscient Pharmaceuticals Inc. is gaining a piece of the fenofibrate market with its buyout of U.S. rights to the once-daily, cholesterol-lowering drug Antara from Reliant Pharmaceuticals Inc. for $78 million. (BioWorld Today)

Inotek Pharmaceuticals Corp.'s Phase II poly-ADP polymerase (PARP) inhibitor program bagged the firm a potential $600 million-plus deal with Genentech Inc., which is paying the privately held company $20 million up front.(BioWorld Today)

Just more than three months after pumping $25 million into Corus Pharma Inc., Gilead Sciences Inc. - already Corus' largest shareholder - is exercising its option to buy out the firm, at a price tag of $365 million. (BioWorld Today)